

PRELIMINARY PROGRAM
as of August 2006

MONDAY, SEPTEMBER 11, 2006

08:00 - 08:30

Opening Session

OPENING REMARKS

M. Bialer, Organizing Committee, Israel

GREETINGS

R.H. Levy, Organizing Committee, USA

E. Perucca, First Vice-President, International League Against Epilepsy (ILAE), Italy

W. Lammert, Epilepsy Therapeutic Drug Project, USA

08:30 - 10:30

**STATUS EPILEPTICUS: UPDATE
AND FUTURE PERSPECTIVES**

Session I - Epidemiology and Current Treatments

Chairpersons:

E. Perucca, Italy

T. Tomson, Sweden

08:30 DEFINITIONS AND CLASSIFICATION
S. Shorvon, UK

08:50 Discussion

09:00 EPIDEMIOLOGY, CONSEQUENCES AND UNMET NEEDS
A.W. Hauser, USA

09:20 Discussion

09:30 EVIDENCE FOR DRUG SELECTION IN EARLY AND REFRACTORY STAGES
K. Malmgren, Sweden

09:50 Discussion

10:00 NEW AEDs IN STATUS EPILEPTICUS
T.P. Bleck, USA

10:20 Discussion

10:30 *Coffee*

MONDAY, SEPTEMBER 11, 2006

11:00 - 14:00

**STATUS EPILEPTICUS: UPDATE
AND FUTURE PERSPECTIVES**

Session II - Development of New Treatments for Status Epilepticus

Chairperson: **E. Abadie**, France
R. Katz, USA

Experimental Models

- 11:00 MODELS FOR ASSESSING DRUGS FOR STATUS EPILEPTICUS
H. Kubova, Czech Republic
- 11:20 Discussion
- 11:30 STATUS EPILEPTICUS MODELS FOR THE IDENTIFICATION OF
NEUROPROTECTIVE SUBSTANCES
H.S. White, USA
- 11:50 Discussion
- 12:00 NEW AGENTS UNDERGOING TESTING FOR STATUS EPILEPTICUS
H.S. White, USA
- 12:20 Discussion

Clinical Testing

- 12:30 OPTIMIZING TRIAL DESIGNS FOR EARLY STATUS EPILEPTICUS
T. Bleck, USA
- 12:50 Discussion
- 13:00 TRIAL DESIGNS FOR REFRACTORY STATUS EPILEPTICUS
S. Shorvon, UK
- 13:20 Discussion
- 13:30 REGULATORY PERSPECTIVES
E. Abadie, France
- 13:50 Discussion

TUESDAY, SEPTEMBER 12, 2006

08:00 - 10:30

Session III - A

DRUGS IN DEVELOPMENT

Chairpersons: **M. Bialer**, Israel
 R.H. Levy, USA

- 08:00 BRIVARACETAM (ucb 34714)
 P. von Rosenstiel, UCB S.A., Belgium
- 08:20 Discussion
- 08:30 ESLICARBAZEPINE ACETATE (BIA 2-093)
 BIAL – Portela & C^a, S.A., Portugal
 Presented by **C.E. Elger**, University of Bonn, Germany
- 08:50 Discussion
- 09:00 FLUOROFELBAMATE
 B.A. Roecklein, *MedPointe Pharmaceuticals*, USA
- 09:20 Discussion
- 09:30 GANAXOLONE
 E. Giller, *Marinus Pharmaceuticals*, USA
- 09:50 Discussion
- 10:00 HUPERZINE
 S. Schachter, Harvard Medical School, USA
- 10:20 Discussion
- 10:30 *Coffee*

TUESDAY, SEPTEMBER 12, 2006

11:00 - 13:00

Session III - B

DRUGS IN DEVELOPMENT

Chairpersons: **S.I. Johannessen**, Norway
 H.J. Kupferberg, USA

11:00 LACOSAMIDE (SPM 927)
 P. Doty and **J. Whitesides**, *Schwarz BioSciences, Inc.*, USA

11:20 Discussion

11:30 RETIGABINE
 R. Porter, *Valeant Pharmaceuticals International*, USA

11:50 Discussion

12:00 RUFINAMIDE
 Eisai, USA
 Presented by **A. Arzimanoglou**, University Hospital Robert Debre,
 Paris, France

12:20 Discussion

12:30 SELETRACETAM (ucb 44212)
 B. Bennett, *UCB Pharma, Inc.*, USA

12:50 Discussion

13:00 *Lunch Break*

TUESDAY, SEPTEMBER 12, 2006

14:30 - 18:00

Session III - C

DRUGS IN DEVELOPMENT

Chairpersons: **B. Schmidt**, Germany
 S. White, USA

- 14:30 STIRIPENTOL
 Presented by **C. Chiron**, Necker-Enfants Malades Hospital, Paris, France
- 14:50 Discussion
- 15:00 TALAMPANEL
 Presented by **M.A. Rogawski**, NIH, USA
- 15:20 Discussion
- 15:30 VALROCEMIDE
 Presented by **M. Bialer**, The Hebrew University of Jerusalem, Israel
- 15:50 Discussion
- 16:00 *Coffee*
- 16:30 JZP-4
 M. Foreman, *Jazz Pharmaceuticals*, USA
- 16:50 Discussion
- 17:00 PID, a second generation to valproic acid
 Jazz Pharmaceuticals, USA
 Presented by **M. Bialer**, The Hebrew University of Jerusalem, Israel
- 17:20 Discussion
- 17:30 RWJ 333369
 G.P. Novak, *Johnson & Johnson Pharmaceutical Research & Development, LLC*,
 USA
- 17:50 Discussion
- 18:00 *Coffee*

TUESDAY, SEPTEMBER 12, 2006

EISAI SPONSORED SATELLITE SYMPOSIUM

All registered participants of the Eighth Eilat Conference on New Antiepileptic Drugs (EILAT VIII) are invited to participate in the Satellite Symposium which will be held at the Melia Sitges, the Conference Venue. Participation is on a "first come first served basis". Kindly mark your intention to participate on the enclosed Registration Form.

18:30 - 20:00

Eisai Sponsored Satellite Symposium

LENNOX-GASTAUT SYNDROME: A DEVELOPING FOCUS

Chairperson: **R. Sachdeo, USA**

THE IMPACT OF LGS: CLINICAL EXPERIENCE
R. Sachdeo, USA

TOWARDS CONSENSUS IN THE MANAGEMENT OF LGS: A CALL TO ACTION
M. Feucht, Austria

RUFINAMIDE: A PHARMACOLOGICAL PROFILE
E. Perucca, Italy

RUFINAMIDE: EFFICACY AND SAFETY DATA
J. Pellock, USA

Concluding remarks and discussion

WEDNESDAY, SEPTEMBER 13, 2006

08:00 - 10:30

Session IV - A

PROGRESS REPORT ON SECOND-GENERATION TREATMENTS

Chairpersons: **I.E. Leppik**, USA
M.Y. Neufeld, Israel

- 08:00 FELBAMATE
MedPointe Pharmaceuticals, USA
Presented by **E. Faught**, University of Alabama, Birmingham, AL, USA
- 08:20 Discussion
- 08:30 GABAPENTIN
Presented by **B. Schmidt**, Wittnau, Germany
- 08:50 Discussion
- 09:00 LAMOTRIGINE
Presented by **F. Besag**, Liverpool, UK
- 09:20 Discussion
- 09:30 LEVETIRACETAM
P. Verdru, *UCB*, USA
- 09:50 Discussion
- 10:00 OXCARBAZEPINE
Novartis Pharma AG, Switzerland
Presented by **D. Nordli**, Children's Memorial Hospital, Chicago, IL, USA
- 10:20 Discussion
- 10:30 *Coffee*

WEDNESDAY, SEPTEMBER 13, 2006

11:00 - 13:00

Session IV - B

PROGRESS REPORT ON SECOND-GENERATION TREATMENTS

Chairpersons: **R.S. Fisher**, USA
 P.H. Ryvlin, France

- 11:00 PREGABALIN
 Pfizer, USA
 Presented by **P.H. Ryvlin**, Hospices Civils de Lyon, Lyon, France
- 11:20 Discussion
- 11:30 TIAGABINE
 Cephalon, Inc., USA
 Presented by **R. Kälviäinen**, Kupio University Hospital, Finland
- 11:50 Discussion
- 12:00 TOPIRAMATE
 E. Cox, *Johnson & Johnson Pharmaceutical Research & Development, LLC*,
 Belgium
- 12:20 Discussion
- 12:30 VIGABATRIN
 Presented by **C. Chiron**, Necker-Enfants Malades Hospital, Paris, France
- 12:50 Discussion
- 13:00 VIGABATRIN
 S. Collins, *Ovation Pharmaceuticals, Inc.*, USA
- 13:20 Discussion
- 13:30 *Lunch Break*

WEDNESDAY, SEPTEMBER 13, 2006

14:30 - 16:30

Session IV - C

PROGRESS REPORT ON SECOND-GENERATION TREATMENTS

Chairpersons: **C.E. Elger**, Germany
 S. Shorvon, UK

- 14:30 ZONISAMIDE
 Eisai, USA
 Presented by **J.A. French**, University of Pennsylvania, Philadelphia, PA,
 USA
- 14:50 Discussion
- 15:00 OXCARBAZEPINE MODIFIED (MR) FORMULATION-CHALLENGES AND
 SUCCESSFUL DEVELOPMENT
 Desitin Arzneimittel GmbH, Hamburg, Germany
 Presented by **H.H. Blume**, Oberursel, Germany
- 15:20 Discussion
- 15:30 NEW ORAL FORMULATIONS OF AEDs: FOCUS ON EXTENDED-
 RELEASE DIVALPROEX
 R.C. Reed, *Abbott Laboratories*, USA
- 15:50 Discussion
- 16:00 VAGUS NERVE STIMULATION
 Cyberonics Europe, Belgium
 Presented by **D. Schmidt**, Epilepsy Research Group, Berlin, Germany
- 16:20 Discussion

THURSDAY, SEPTEMBER 14, 2006

08:30 - 10:00

Session V

EVIDENCE-BASED TREATMENT GUIDELINES

Chairpersons: **R. Kälviäinen**, Finland
P. Wolf, Denmark

08:30 THE AAN GUIDELINES
J.A. French, USA

08:50 Discussion

09:00 THE ILAE GUIDELINES
T. Tomson, Sweden

09:20 Discussion

09:30 **Panel Discussion:**
VALUE AND CONSEQUENCES FOR PATIENTS, PRESCRIBERS AND THE
INDUSTRY
J.A. French, USA, **D. Schmidt**, Germany, **T. Tomson**, Sweden
and other speakers to be announced

10:00 *Coffee*

10:30 - 12:00

Session VI

NEURO-STIMULATION IN REFRACTORY EPILEPSY

Chairpersons: **S.I. Johannessen**, Norway
E. Perucca, Italy

10:30 THE EXPERIMENTAL BASIS FOR NEURO-STIMULATION
P. Ryvlin, France

10:50 Discussion

11:00 DESIGNING CLINICAL TRIALS OF NEURO-STIMULATION IN EPILEPSY
R.S. Fisher, USA

11:20 Discussion

11:30 NEURO-STIMULATION IN EPILEPSY: CLINICAL DATA
P. Boon, Belgium

11:50 Discussion